Claims for Patent: 11,253,491

Summary for Patent: 11,253,491

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US17/193,340
Patent Claims:	1. A method of treating major depressive disorder comprising orally administering a dosage form for at least 8 consecutive days to a human being in need thereof, wherein the dosage form contains about 30 mg to about 60 mg of a dextromethorphan and about 50 mg to about 200 mg of a bupropion as the only active pharmaceutical ingredients in the dosage form, wherein the human being is suffering from major depressive disorder with suicidal ideation. 2. The method of claim 1, wherein the dosage form contains about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan. 3. The method of claim 2, wherein the dosage form contains about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 4. The method of claim 1, wherein the dosage form contains about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 5. The method of claim 2, wherein the dosage form contains about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 6. The method of claim 1, wherein the dosage form contains about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 7. The method of claim 1, wherein the dosage form provides immediate release of dextromethorphan and sustained release of bupropion. 8. The method of claim 1, wherein the human being is suffering from treatment resistant major depressive disorder with suicidal ideation. 9. The method of claim 8, wherein the dosage form contains about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan. 10. The method of claim 9, wherein the dosage form contains about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 11. The method of claim 8, wherein the dosage form contains about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 12. The method of claim 9, wherein the dosage form contains about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 13. The method of claim 8, wherein the dosage form contains about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 14. The method of claim 8, wherein the dosage form provides immediate release of dextromethorphan and sustained release of bupropion. 15. A method of treating major depressive disorder comprising orally administering a dosage form for at least 8 consecutive days to a human being in need thereof, wherein the dosage form contains about 30 mg to about 60 mg of a dextromethorphan and about 50 mg to about 200 mg of a bupropion as the only active pharmaceutical ingredients in the dosage form, wherein the human being is suffering from major depressive disorder with suicidal thoughts or attempts. 16. The method of claim 15, wherein the dosage form contains about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan. 17. The method of claim 16, wherein the dosage form contains about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 18. The method of claim 15, wherein the dosage form contains about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 19. The method of claim 16, wherein the dosage form contains about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 20. The method of claim 15, wherein the dosage form contains about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 21. The method of claim 15, wherein the dosage form provides immediate release of dextromethorphan and sustained release of bupropion. 22. The method of claim 15, wherein the human being is suffering from treatment resistant major depressive disorder with suicidal thoughts or attempts. 23. The method of claim 22, wherein the dosage form contains about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan. 24. The method of claim 23, wherein the dosage form contains about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 25. The method of claim 22, wherein the dosage form contains about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 26. The method of claim 23, wherein the dosage form contains about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 27. The method of claim 22, wherein the dosage form contains about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion. 28. The method of claim 22, wherein the dosage form provides immediate release of dextromethorphan and sustained release of bupropion. 29. The method of claim 1, wherein the human being experiences resolution of the suicidal ideation by the eighth day of treatment. 30. The method of claim 15, wherein the human being experiences resolution of the suicidal thoughts or attempts by the eighth day of treatment.